Acute Lymphoblastic Leukemia, Version 2.2015

Joseph Alvarnas(City Of Hope National Medical Center), Patrick A. Brown(Johns Hopkins University), Patricia Aoun(City Of Hope National Medical Center), Karen K. Ballen(Harvard University Press), Stefan K. Barta(University of Michigan–Ann Arbor), Uma Borate(University of Alabama at Birmingham), Michael W. Boyer(University of Michigan–Ann Arbor), Patrick W. Burke(University of Michigan–Ann Arbor), Ryan D. Cassaday(University of Michigan–Ann Arbor), Januario E. Castro(University of California, San Diego), Peter F. Coccia(University of Nebraska Medical Center), Steven Coutré(University of Michigan–Ann Arbor), Lloyd E. Damon(University of California, San Francisco), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Dan Douer(Memorial Sloan Kettering Cancer Center), Olga Frankfurt(Northwestern University), John P. Greer(Vanderbilt University), Robert A. Johnson(University of Tennessee Health Science Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Rebecca B. Klisovic(The Ohio State University), Gary M. Kupfer(Yale Cancer Center), Mark R. Litzow(Mayo Clinic), Arthur Liu(University of Colorado Boulder), Arati V. Rao(Duke University), Bijal Shah(University of South Florida), Geoffrey L. Uy(Washington University in St. Louis), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Kristina M. Gregory(National Comprehensive Cancer Network), Courtney Smith(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
October 1, 2015
10.6004/jnccn.2015.0153
Cited by 245Open Access
Full Text

Abstract

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.

Related Papers

No related papers found

Powered by citation graph analysis